Anti-IL1 therapy for severe FOP flare-ups
Part of Bones, joints & muscles clinical trials.
This trial is for people with FOP who have severe, frequent flare-ups. It follows those who are already starting an anti-IL1 medication (like anakinra) to see if it helps reduce flares and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with classic FOP (the R206H gene change) and are between 6 and 30 years old.
- You have frequent flare-ups—more than 4 per year—or a flare that has lasted over a month without getting better.
- Your doctor has already decided to start you on an anti-IL1 medication (like anakinra or canakinumab).
- You are able to travel to UCSF for study visits, blood draws, and scans.
- You do not have a history of unexplained infections, autoimmune disease, or a reason you cannot take anti-IL1 therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether INCB000928 can safely help people with fibrodysplasia ossificans progressiva (FOP). It mainly looks at whether the treatment is effective and well-tolerated, and it involves scheduled whole-body scans using low-dose X-rays.
This trial is a registry that collects information from people with fibrodysplasia ossificans progressiva (FOP). It helps researchers better understand the condition and use that knowledge for future studies that could lead to better care.
This study tracks the long-term safety and how well palovarotene works in people with FOP who are already taking it as part of their regular care. By joining, you help doctors learn more about the medicine over time.
This trial tests a new drug called garetosmab in children and teens with fibrodysplasia ossificans progressiva (FOP), a rare condition where muscle and soft tissue turn into bone. The goal is to see if garetosmab can help prevent or slow down these abnormal bone growths.
This trial tests a new medicine, ORJ-001, for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help slow the disease and improve breathing.
This trial tests if a new drug called F8IL10, given as an injection directly into an inflamed joint, can help people with rheumatoid arthritis. It is for adults who have had RA for more than 6 months and still have joint swelling despite their current medications.
Hear when a new Fibrodysplasia Ossificans Progressiva (FOP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.